PGI28 Cost-Effectiveness of Simeprevir Vs. Telaprevir for The Triple Therapy of Hepatitis C In Kazakhstan

Bektur, C; Nurgozhin, T; Abdukhakimova, D

Басты бет
→
01.NU Schools
→
School of Medicine
→
Articles
→
Элементті қарап шығу

Кеңейтілген іздеу

Система будет остановлена для регулярного обслуживания. Пожалуйста, сохраните рабочие данные и выйдите из системы.

PGI28 Cost-Effectiveness of Simeprevir Vs. Telaprevir for The Triple Therapy of Hepatitis C In Kazakhstan

Bektur, C; Nurgozhin, T; Abdukhakimova, D

URI: https://www.sciencedirect.com/science/article/pii/S1098301515042850
http://nur.nu.edu.kz/handle/123456789/2861

Күні: 2015-11-01

Аннотация:

Hepatitis C Virus(HCV) is a growing health problem in the world. The aim of this study is to estimate a cost-effectiveness of a triple therapy(TT) with simeprevir compared to a TT with telaprevir for the previously treated with double therapy HCV patients in Kazakhstan.

Толық ақпаратты көрсету